Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 1,081–1,090 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1081

    Medicine slug
    nevirapine
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    9
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 24 hrs

      Numeric value
      24
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2620b114-f53f-44f1-8708-697e86343090 (opens source in a new tab)

        Nevirapine label

        Version not recorded · Effective date not recorded

        Nevirapine was absorbed with a median t max of approximately 24 hrs.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:690da74b-2481-47fc-93ae-8340e0caf0a4 (opens source in a new tab)

        Nevirapine label

        Version not recorded · Effective date not recorded

        Nevirapine was absorbed with a median t max of approximately 24 hrs.

  2. Projected row 1082

    Medicine slug
    nevirapine
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    9
    Source count
    9
    Agreement rate
    1
    Recorded readings

    1. 1.21 ± 0.09 L/kg

      Numeric value
      1.21
      Unit
      L/kg
      Source records
      9

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 9 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:effb86cc-4b80-4fac-aaa3-9f373b3d0f7d (opens source in a new tab)

        Nevirapine label

        Version not recorded · Effective date not recorded

        Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is widely distributed in humans.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8dfe86aa-ea5d-48d2-94a8-1a5506055d70 (opens source in a new tab)

        Nevirapine label

        Version not recorded · Effective date not recorded

        Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is widely distributed in humans.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4f065674-4719-4c79-ba0d-549040d77f17 (opens source in a new tab)

        Nevirapine label

        Version not recorded · Effective date not recorded

        Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is widely distributed in humans.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:61409678-d2f6-42cd-b03d-b26b11b39641 (opens source in a new tab)

        Nevirapine label

        Version not recorded · Effective date not recorded

        Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is widely distributed in humans.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2620b114-f53f-44f1-8708-697e86343090 (opens source in a new tab)

        Nevirapine label

        Version not recorded · Effective date not recorded

        Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is widely distributed in humans.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbd628db-4076-4fe0-8323-9cc33ae92e42 (opens source in a new tab)

        Nevirapine label

        Version not recorded · Effective date not recorded

        Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is widely distributed in humans.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f6c3eed-2a5d-46ed-9a7c-59715f338a15 (opens source in a new tab)

        Nevirapine label

        Version not recorded · Effective date not recorded

        Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is widely distributed in humans.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:690da74b-2481-47fc-93ae-8340e0caf0a4 (opens source in a new tab)

        Nevirapine label

        Version not recorded · Effective date not recorded

        Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is widely distributed in humans.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6e93829-7024-48f6-8023-da6ff27dfc0a (opens source in a new tab)

        Nevirapine label

        Version not recorded · Effective date not recorded

        Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is widely distributed in humans.

  3. Projected row 1083

    Medicine slug
    niacin
    Compared field
    bioavailability
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    14
    Source count
    11
    Agreement rate
    0.727273
    Recorded readings

    1. 2 to 3%

      Numeric value
      2
      Unit
      %
      Source records
      8

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 8 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52ad4a6a-81cc-4b03-b8b1-3bd9a1d4064e (opens source in a new tab)

        Niacin label

        Version not recorded · Effective date not recorded

        Lovastatin reduced niacin extended-release tablets bioavailability by 2 to 3% [see Drug Interactions ( 7.1 )].
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:249e27ac-e1e7-42dc-84f6-cd32fd1d9dee (opens source in a new tab)

        Niacin label

        Version not recorded · Effective date not recorded

        Lovastatin reduced niacin extended-release tablets bioavailability by 2-3% [see Drug Interactions ( 7.1 )] .
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e290f96-e8c6-47fd-863f-1c9480f28d9b (opens source in a new tab)

        Niacin label

        Version not recorded · Effective date not recorded

        Lovastatin reduced niacin extended-release bioavailability by 2 to 3% [see Drug Interactions ( 7.1 )].
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8eff9205-84ac-e69d-e053-2995a90aad4b (opens source in a new tab)

        Niacin label

        Version not recorded · Effective date not recorded

        Lovastatin reduced niacin extended-release tablets bioavailability by 2-3% [see Drug Interactions ( 7.1 )] .
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7b66e13-00ed-48a9-a54a-8e474cc31d54 (opens source in a new tab)

        Niacin label

        Version not recorded · Effective date not recorded

        Lovastatin reduced niacin extended-release tablets bioavailability by 2-3% [see Drug Interactions ( 7.1 )] .
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43233a21-3f90-4c69-bbeb-f50d5f2d35ae (opens source in a new tab)

        Niacin label

        Version not recorded · Effective date not recorded

        Lovastatin reduced niacin extended-release tablets bioavailability by 2 to 3% [see Drug Interactions (7.1) ] .
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:568c3a99-b6e8-48b4-bb68-867bbcefa027 (opens source in a new tab)

        Niacin label

        Version not recorded · Effective date not recorded

        Lovastatin reduced niacin extended-release tablets bioavailability by 2-3% [see Drug Interactions ( 7.1 )] .
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:92b3ec1d-0dc7-4bde-9817-57b1bdf7f0b9 (opens source in a new tab)

        Niacin label

        Version not recorded · Effective date not recorded

        Lovastatin reduced niacin extended-release tablets bioavailability by 2 to 3% [see Drug Interactions ( 7.1 )].

    2. 2%

      Numeric value
      2
      Unit
      %
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e604319-e164-4056-ab80-b78b98c519c7 (opens source in a new tab)

        Niacin label

        Version not recorded · Effective date not recorded

        Lovastatin reduced niacin extended-release bioavailability by 2% to 3% [see Drug Interactions (7.1) ] .
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd60fe81-3d54-4a29-9502-601be89c575e (opens source in a new tab)

        Niacin label

        Version not recorded · Effective date not recorded

        Lovastatin reduced niacin extended-release bioavailability by 2% to 3% [see Drug Interactions (7.1) ] .
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7250313b-b2ef-4736-bd25-2f29c2ac0eb9 (opens source in a new tab)

        Niacin label

        Version not recorded · Effective date not recorded

        Lovastatin reduced niacin extended-release bioavailability by 2% to 3% [see Drug Interactions (7.1) ] .

  4. Projected row 1084

    Medicine slug
    nicardipine
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    34
    Source count
    9
    Agreement rate
    1
    Recorded readings

    1. 35%

      Numeric value
      35
      Unit
      %
      Source records
      9

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 9 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:edda985c-004e-4487-b856-13cf2cdb900f (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        While nicardipine hydrochloride capsules are completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30-mg oral dose at steady-state.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:575c5dab-e832-192a-e063-6294a90a34a1 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        While nicardipine hydrochloride capsules are completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30-mg oral dose at steady-state.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:065efabf-8c7d-4dd5-aef2-700c2eca399d (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        While nicardipine hydrochloride capsules are completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30-mg oral dose at steady-state.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb902af0-b5ad-4680-b2f2-007ef2196efe (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        While nicardipine hydrochloride capsules are completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30-mg oral dose at steady-state.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1e275b8-c71a-4e8b-bca0-cfea048b5343 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        While nicardipine hydrochloride is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30-mg oral dose at steady-state.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79304b0f-53d3-4065-8c81-7031d1141694 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        While nicardipine hydrochloride is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady‑state.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8f147b8-955f-4733-9178-2cfa0beb60d6 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        While nicardipine hydrochloride capsules are completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30-mg oral dose at steady-state.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7bed5d8c-30c2-4598-acf3-2edba825a56d (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        While nicardipine hydrochloride capsules are completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30-mg oral dose at steady-state.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3955d43d-a87f-4d2c-b90e-3ecf0d6aa148 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        While nicardipine hydrochloride is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30-mg oral dose at steady-state.

  5. Projected row 1085

    Medicine slug
    nicardipine
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    34
    Source count
    34
    Agreement rate
    0.411765
    Recorded readings

    1. 14.4 hours

      Numeric value
      14.4
      Unit
      hours
      Source records
      14

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 14 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a3e33add-0d09-423a-9109-42e5ba7148d5 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α-half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9ffe6b6f-b8bc-413f-9bec-7639e9d71d3d (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α-half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c576c9d5-853b-4e93-be6c-3579dfa5564c (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α−half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dcd7d173-4d8e-4282-9edf-817711340e43 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α−half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5499cfac-9147-4d5d-a8cb-f8d64f1481af (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α-half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5749599d-ff2a-42e4-aa72-cd25013feee8 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α-half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0070638-bea5-413a-8658-4c752c6104f5 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α-half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:372a4381-7302-4df7-81bb-a9521907f867 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α−half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0e2bed3-f928-43ab-a05c-275bedc9856f (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α-half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7433b5cd-9c3a-428a-bcaf-00f02cd52633 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α-half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30fb3a4d-fa75-42fd-b4b6-2a21f202027f (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α-half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f12cea0d-b7cd-41d8-b551-2c74cc7f5f4e (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α-half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76fcb7e0-9034-4fcd-be14-ce7e9ccaee2a (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α-half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f5d3050-9cdf-404f-ac0f-72399178959f (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline tri-exponentially, with a rapid early distribution phase (α−half-life of 2.7 minutes), an intermediate phase (β-half-life of 44.8 minutes), and a slow terminal phase (γ-half-life of 14.4 hours) that can only be detected after long-term infusions.

    2. 14 hours

      Numeric value
      14
      Unit
      hours
      Source records
      11

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 11 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d898911-d811-2a78-e053-2995a90af784 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α-half-life of 3 minutes), an intermediate phase (ß-half-life of 45 minutes), and a slow terminal phase (ƴ-half-life of 14 hours) that can only be detected after long-term infusions.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55bd6dcc-1f12-4378-8e9e-1ceed26818f5 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α-half-life of 3 minutes), an intermediate phase (ß-half-life of 45 minutes), and a slow terminal phase (ƴ-half-life of 14 hours) that can only be detected after long-term infusions.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8b49f59-7a54-425d-9eca-dfa4022a08d1 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α-half-life of 3 minutes), an intermediate phase (β-half-life of 45 minutes), and a slow terminal phase (γ -half-life of 14 hours) that can only be detected after long-term infusions.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e8611e0-7d8c-4f30-b53a-76c6588b6ef7 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α-half-life of 3 minutes), an intermediate phase (β-half-life of 45 minutes), and a slow terminal phase (γ-half-life of 14 hours) that can only be detected after long-term infusions.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:570af1f8-6718-4b40-ae89-0f738d330ebd (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α-half-life of 3 minutes), an intermediate phase (β-half-life of 45 minutes), and a slow terminal phase (ƴ-half-life of 14 hours) that can only be detected after long-term infusions.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0eb7d839-63d9-4b51-bf7b-4a8fde6339b5 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α-half-life of 3 minutes), an intermediate phase (ß-half-life of 45 minutes), and a slow terminal phase (ƴ-half-life of 14 hours) that can only be detected after long-term infusions.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9383f1dc-0310-4c87-a8f0-48c09a85d89b (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α-half-life of 3 minutes), an intermediate phase (β-half-life of 45 minutes), and a slow terminal phase (γ -half-life of 14 hours) that can only be detected after long-term infusions.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cdafe6cc-b03e-4e72-9d0a-6baa977149d6 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α- half-life of 3 minutes), an intermediate phase (ß-half-life of 45 minutes), and a slow terminal phase (ƴ-half-life of 14 hours) that can only be detected after long-term infusions.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18fb1c2b-0c1e-436c-a5b6-d4840b5da228 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α-half-life of 3 minutes), an intermediate phase (ß-half-life of 45 minutes), and a slow terminal phase (ƴ-half-life of 14 hours) that can only be detected after long-term infusions.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7226a518-164b-4755-9624-1cc75c939063 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α-half-life of 3 minutes), an intermediate phase (ß-half-life of 45 minutes), and a slow terminal phase (ƴ-half-life of 14 hours) that can only be detected after long-term infusions.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:433dbca3-0a86-44c2-835d-1051c1c93878 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α- half-life of 3 minutes), an intermediate phase (ß-half-life of 45 minutes), and a slow terminal phase (ƴ-half-life of 14 hours) that can only be detected after long-term infusions.

    3. 8.6 hours

      Numeric value
      8.6
      Unit
      hours
      Source records
      9

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 9 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:edda985c-004e-4487-b856-13cf2cdb900f (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Post-absorption kinetics of nicardipine hydrochloride capsules are also non-linear, although there is a reproducible terminal plasma half-life that averaged 8.6 hours following 30- and 40-mg doses at steady-state (tid).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:575c5dab-e832-192a-e063-6294a90a34a1 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Post-absorption kinetics of nicardipine hydrochloride capsules are also non-linear, although there is a reproducible terminal plasma half-life that averaged 8.6 hours following 30- and 40-mg doses at steady-state (tid).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:065efabf-8c7d-4dd5-aef2-700c2eca399d (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Post-absorption kinetics of nicardipine hydrochloride capsules are also non-linear, although there is a reproducible terminal plasma half-life that averaged 8.6 hours following 30- and 40-mg doses at steady-state (tid).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb902af0-b5ad-4680-b2f2-007ef2196efe (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Post-absorption kinetics of nicardipine hydrochloride capsules are also non-linear, although there is a reproducible terminal plasma half-life that averaged 8.6 hours following 30- and 40-mg doses at steady-state (tid).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1e275b8-c71a-4e8b-bca0-cfea048b5343 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Post-absorption kinetics of nicardipine hydrochloride capsules are also non-linear, although there is a reproducible terminal plasma half-life that averaged 8.6 hours following 30- and 40-mg doses at steady-state (tid).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79304b0f-53d3-4065-8c81-7031d1141694 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Post-absorption kinetics of nicardipine hydrochloride are also non-linear, although there is a reproducible terminal plasma half-life that averaged 8.6 hours following 30 mg and 40 mg doses at steady‑state (tid).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8f147b8-955f-4733-9178-2cfa0beb60d6 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Post-absorption kinetics of nicardipine hydrochloride capsules are also non-linear, although there is a reproducible terminal plasma half-life that averaged 8.6 hours following 30- and 40-mg doses at steady-state (tid).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7bed5d8c-30c2-4598-acf3-2edba825a56d (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Post-absorption kinetics of nicardipine hydrochloride capsules are also non-linear, although there is a reproducible terminal plasma half-life that averaged 8.6 hours following 30- and 40-mg doses at steady-state (tid).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3955d43d-a87f-4d2c-b90e-3ecf0d6aa148 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Post-absorption kinetics of nicardipine hydrochloride are also non-linear, although there is a reproducible terminal plasma half-life that averaged 8.6 hours following 30- and 40-mg doses at steady-state (tid).

  6. Projected row 1086

    Medicine slug
    nicardipine
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    34
    Source count
    25
    Agreement rate
    1
    Recorded readings

    1. 8.3 L/kg

      Numeric value
      8.3
      Unit
      L/kg
      Source records
      25

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 25 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a3e33add-0d09-423a-9109-42e5ba7148d5 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9ffe6b6f-b8bc-413f-9bec-7639e9d71d3d (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d898911-d811-2a78-e053-2995a90af784 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c576c9d5-853b-4e93-be6c-3579dfa5564c (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dcd7d173-4d8e-4282-9edf-817711340e43 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5499cfac-9147-4d5d-a8cb-f8d64f1481af (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5749599d-ff2a-42e4-aa72-cd25013feee8 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0070638-bea5-413a-8658-4c752c6104f5 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr · kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:372a4381-7302-4df7-81bb-a9521907f867 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55bd6dcc-1f12-4378-8e9e-1ceed26818f5 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8b49f59-7a54-425d-9eca-dfa4022a08d1 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e8611e0-7d8c-4f30-b53a-76c6588b6ef7 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:570af1f8-6718-4b40-ae89-0f738d330ebd (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0e2bed3-f928-43ab-a05c-275bedc9856f (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7433b5cd-9c3a-428a-bcaf-00f02cd52633 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0eb7d839-63d9-4b51-bf7b-4a8fde6339b5 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30fb3a4d-fa75-42fd-b4b6-2a21f202027f (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f12cea0d-b7cd-41d8-b551-2c74cc7f5f4e (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9383f1dc-0310-4c87-a8f0-48c09a85d89b (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76fcb7e0-9034-4fcd-be14-ce7e9ccaee2a (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cdafe6cc-b03e-4e72-9d0a-6baa977149d6 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18fb1c2b-0c1e-436c-a5b6-d4840b5da228 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7226a518-164b-4755-9624-1cc75c939063 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f5d3050-9cdf-404f-ac0f-72399178959f (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (V d ) using a non-compartment model is 8.3 L/kg.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:433dbca3-0a86-44c2-835d-1051c1c93878 (opens source in a new tab)

        Nicardipine label

        Version not recorded · Effective date not recorded

        Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.

  7. Projected row 1087

    Medicine slug
    nifedipine
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    89
    Source count
    56
    Agreement rate
    1
    Recorded readings

    1. 86%

      Numeric value
      86
      Unit
      %
      Source records
      56

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 56 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5927fcff-9d1a-8322-e053-2991aa0ad289 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8358be1-848c-d9eb-e053-6294a90a178c (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d3e11d2-d320-45d3-96c8-48322202b504 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ab8945b-bea5-9827-e063-6294a90af334 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cda16a27-f029-40a6-a0e8-2bed0de71169 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c98ecf77-ae9a-438b-9bad-ffbed25d95bc (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b885b6b5-71c6-4799-8b23-5ee8c17938a0 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75003769-7800-4bc7-b709-35b4caec2c2f (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the Nifedipine Extended-release Tablet is 86% relative to immediate-release capsules.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:325acf27-4b2e-40e8-8344-bb6cc9959910 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1a78ff2-7672-3e69-00ef-63d203c80484 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the Nifedipine Extended-release Tablet is 86% relative to immediate-release capsules.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac3f68b2-29b5-45c1-b6a2-54704dc3143e (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f32c0fc9-b4ad-6a1f-e053-2995a90acf61 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2f3564a-d43a-6c36-e053-2a95a90ae878 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09a04e5f-d3b0-4ee3-b12d-f74203262179 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71a4e00b-8386-4da1-8515-a0e7e8db104d (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a68f67f-5b68-4f83-aad8-fc3177f5a0a4 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:657221d5-9eb8-42f9-8cdc-39cefc386f51 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a84be46e-bb0c-d59f-e053-2a95a90aabde (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a7951e7-f507-43e8-9bba-855b79daf170 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:160271a8-7922-2107-e054-00144ff88e88 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41aa6fbd-96c1-40f7-92d4-cfdd2d5325e9 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3bf4282f-b063-4d35-8ef0-6f48b98e9deb (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:593d8ca3-c303-4512-96a6-d4860e02cd83 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the Nifedipine Extended-release Tablet is 86% relative to immediate-release capsules.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:446505e8-cd68-4037-bebe-954a893dc67b (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3334ab6f-aeb0-4b78-8d17-f0aedd94f996 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32526983-f53a-fa68-e063-6394a90aa13f (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1add684f-d082-72cc-e063-6394a90a1214 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ee466dc-5a4e-4c77-8e94-8b510cafd61b (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b11026f8-dea0-49ac-8725-0ef7dc27923f (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the Nifedipine Extended-release Tablet is 86% relative to immediate-release capsules.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63f062f6-5669-434c-8ded-9801d8486dbf (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0cabe053-3b7e-4dcb-8441-ef7821bb6f68 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:89723620-474e-4b16-9f57-4e927efc401c (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24e56333-5601-48fd-a263-f6be90983fb4 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7475c68-6310-4b9a-81c1-9209a9ade75f (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ebcb33c-f43b-4b36-9f94-9774b2a59e06 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the PROCARDIA XL Extended Release Tablet is 86% relative to PROCARDIA capsules.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f661c1d9-f0f6-4595-82dd-f656bff974f1 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec13ec71-626f-4664-b264-f67ba72071ae (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state the bioavailability of the Nifedipine Extended-release Tablet is 86% relative to immediate-release capsules.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:838d6e8f-37b0-48d3-b701-c4fa32a87b85 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c4f8a8e-3995-4d2e-85d4-b6a45f5fac3e (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86c1bdae-c749-4ec3-90f6-7ebe8e76c461 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the Nifedipine Extended-release Tablet is 86% relative to immediate-release capsules.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3b04484-f330-9523-e053-2995a90a0e45 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d428aa4d-4cc0-4b1e-b9f6-40ae65a735d6 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b6418a8-600f-470e-adf1-56207bb25c38 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the Nifedipine Extended-release Tablet is 86% relative to immediate-release capsules.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a4d5b67-6ce7-4098-9324-f68084e800e4 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e5e126a-7da6-4ceb-b72b-5c9dcc7d7769 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7874606-c71e-424c-b881-38697988e0d0 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1cd5011-b80e-4b1b-8729-56260b8b3c26 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da565525-c77a-0571-e053-2995a90aaa11 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:518d39af-0be1-acbc-e063-6294a90a4ada (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f64a8d7-dfbf-4a81-81bd-b09cfe7cbd44 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1486f187-0ec6-4c70-8991-02c1493912b4 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7160331a-8735-4bc0-8cb9-a8014512a669 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:331db003-cc8e-4509-9415-20e48c5cc5b2 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the Nifedipine Extended-release Tablet is 86% relative to immediate-release capsules.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5df10bc-16ed-7a97-e053-2a95a90ab15e (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:832fc274-605a-4b04-b327-dbf361131621 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state, the bioavailability of the nifedipine extended-release tablets is 86% relative to nifedipine capsules.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a8e3090-7733-4914-bacb-01bbdc8deb30 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        At steady-state the bioavailability of the Nifedipine Extended-release Tablet is 86% relative to immediate-release capsules.

  8. Projected row 1088

    Medicine slug
    nifedipine
    Compared field
    proteinBinding
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    89
    Source count
    88
    Agreement rate
    0.715909
    Recorded readings

    1. 92 to 98%

      Numeric value
      92
      Unit
      %
      Source records
      63

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 63 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bddfd658-ac61-4ba2-a3fa-07acc35d368a (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5927fcff-9d1a-8322-e053-2991aa0ad289 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8358be1-848c-d9eb-e053-6294a90a178c (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d3e11d2-d320-45d3-96c8-48322202b504 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ab8945b-bea5-9827-e063-6294a90af334 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:acb493a3-b8f2-41a9-8ab2-550d97c4592a (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cda16a27-f029-40a6-a0e8-2bed0de71169 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c98ecf77-ae9a-438b-9bad-ffbed25d95bc (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b885b6b5-71c6-4799-8b23-5ee8c17938a0 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75003769-7800-4bc7-b709-35b4caec2c2f (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92-98%).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:325acf27-4b2e-40e8-8344-bb6cc9959910 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1a78ff2-7672-3e69-00ef-63d203c80484 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac3f68b2-29b5-45c1-b6a2-54704dc3143e (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f32c0fc9-b4ad-6a1f-e053-2995a90acf61 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2f3564a-d43a-6c36-e053-2a95a90ae878 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8b8cfee-ea71-44c2-81af-675efecfdf15 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09a04e5f-d3b0-4ee3-b12d-f74203262179 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71a4e00b-8386-4da1-8515-a0e7e8db104d (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a68f67f-5b68-4f83-aad8-fc3177f5a0a4 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:657221d5-9eb8-42f9-8cdc-39cefc386f51 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a84be46e-bb0c-d59f-e053-2a95a90aabde (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5014847e-389d-48c1-8350-b9b24ca8d2a4 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a7951e7-f507-43e8-9bba-855b79daf170 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:160271a8-7922-2107-e054-00144ff88e88 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41aa6fbd-96c1-40f7-92d4-cfdd2d5325e9 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3bf4282f-b063-4d35-8ef0-6f48b98e9deb (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b0263a7-c492-40ea-e053-2a95a90a561e (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:593d8ca3-c303-4512-96a6-d4860e02cd83 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92-98%).
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:446505e8-cd68-4037-bebe-954a893dc67b (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3334ab6f-aeb0-4b78-8d17-f0aedd94f996 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32526983-f53a-fa68-e063-6394a90aa13f (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1add684f-d082-72cc-e063-6394a90a1214 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ee466dc-5a4e-4c77-8e94-8b510cafd61b (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b11026f8-dea0-49ac-8725-0ef7dc27923f (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92-98%).
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63f062f6-5669-434c-8ded-9801d8486dbf (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0cabe053-3b7e-4dcb-8441-ef7821bb6f68 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:89723620-474e-4b16-9f57-4e927efc401c (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24e56333-5601-48fd-a263-f6be90983fb4 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7475c68-6310-4b9a-81c1-9209a9ade75f (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ebcb33c-f43b-4b36-9f94-9774b2a59e06 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f661c1d9-f0f6-4595-82dd-f656bff974f1 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec13ec71-626f-4664-b264-f67ba72071ae (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92-98%).
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:838d6e8f-37b0-48d3-b701-c4fa32a87b85 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c4f8a8e-3995-4d2e-85d4-b6a45f5fac3e (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86c1bdae-c749-4ec3-90f6-7ebe8e76c461 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92-98%).
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3b04484-f330-9523-e053-2995a90a0e45 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d428aa4d-4cc0-4b1e-b9f6-40ae65a735d6 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b6418a8-600f-470e-adf1-56207bb25c38 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92-98%).
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a4d5b67-6ce7-4098-9324-f68084e800e4 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e5e126a-7da6-4ceb-b72b-5c9dcc7d7769 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7874606-c71e-424c-b881-38697988e0d0 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92-98%).
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e1cd5011-b80e-4b1b-8729-56260b8b3c26 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51cdb22b-035f-47d7-8048-38006e2589f2 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da565525-c77a-0571-e053-2995a90aaa11 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:518d39af-0be1-acbc-e063-6294a90a4ada (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f64a8d7-dfbf-4a81-81bd-b09cfe7cbd44 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:472621b6-c2b7-4582-9ceb-7cead55ff247 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1486f187-0ec6-4c70-8991-02c1493912b4 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7160331a-8735-4bc0-8cb9-a8014512a669 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92 to 98%).
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:331db003-cc8e-4509-9415-20e48c5cc5b2 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92-98%).
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5df10bc-16ed-7a97-e053-2a95a90ab15e (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:832fc274-605a-4b04-b327-dbf361131621 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92–98%).
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a8e3090-7733-4914-bacb-01bbdc8deb30 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of serum protein binding of nifedipine is high (92-98%).

    2. 92%

      Numeric value
      92
      Unit
      %
      Source records
      25

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 25 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b98b011-793c-ed92-e063-6294a90ac2bc (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca5b0178-4e5f-4077-ada5-7058b0a03858 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95a53fc5-852d-4892-af20-2aaece9399ba (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92% to 98%).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af5a6330-1819-4724-9f08-da45ac9fb478 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92% to 98%).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7dc5eec6-f32a-45e6-af24-830738cae471 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92% to 98%).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27d6c9c5-5a45-9cfc-e063-6394a90a7202 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92% to 98%).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eb70b7ff-f9f0-41d0-901a-f4c04ae9ed46 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92% to 98%).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1bd05e73-5104-4ef7-a705-22e2db140354 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92% to 98%).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5432254e-ce27-4a67-9eba-e06e092cb93d (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92% to 98%).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb6d8f32-198e-4ccf-bf25-069c03d624fd (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:888b3fac-2f2f-42b8-92d1-d37b6ed225a5 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36b07283-fc0e-4a14-b78f-1d2ab80e7f31 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92% to 98%).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1c857df2-9cce-40de-95c3-b1274ed1e1bc (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81e6c8e7-e826-4abb-ad58-1dee62091a66 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92% to 98%).
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75bb3a1f-3cb7-4450-8e59-27521a1ebc25 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b0ae3ed-77ee-d0df-e063-6294a90a7d17 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92% to 98%).
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9a501be-8523-3924-e053-2995a90a8569 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59724871-b495-4911-a86d-20069ec42edd (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92% to 98%).
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb9d013a-2303-4e1d-a539-8ff04d5ec91d (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:925e2ea9-f51a-4b89-ab5d-ce590b6c4d85 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb051508-60f3-4b89-9da0-5261024bd7f4 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9dec600-4e11-8292-e053-2a95a90a6842 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92% to 98%).
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da80fa84-9336-082c-e053-2a95a90a8987 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b4e9bbc-4c16-4611-9ea2-903852804227 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d02eba2-e964-4fa7-aaae-25949b5f0316 (opens source in a new tab)

        Nifedipine label

        Version not recorded · Effective date not recorded

        The degree of protein binding of nifedipine is high (92%-98%).

  9. Projected row 1089

    Medicine slug
    nilotinib
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    11
    Source count
    7
    Agreement rate
    1
    Recorded readings

    1. 50%

      Numeric value
      50
      Unit
      %
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13b46e09-62d2-4ce9-b3c0-deafcb1f1842 (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Absorption Relative bioavailability of nilotinib capsule is approximately 50%, as compared to an oral drink solution (pH of 1.2 to 1.3).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6093952a-5248-45cb-ad17-33716a411146 (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Absorption Relative bioavailability of nilotinib capsule is approximately 50%, as compared to an oral drink solution (pH of 1.2 to 1.3).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:805cc504-60bb-7743-5ada-679eb3badc7f (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Absorption Relative bioavailability of nilotinib capsule is approximately 50%, as compared to an oral drink solution (pH of 1.2 to 1.3).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86dc5507-ae0a-43d2-8d5e-5b0568ce9c5e (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Absorption Relative bioavailability of nilotinib capsule is approximately 50%, as compared to an oral drink solution (pH of 1.2 to 1.3).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b34e7fd4-53c5-46d8-bf8a-1fcbe7a16504 (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Absorption Relative bioavailability of nilotinib capsule is approximately 50%, as compared to an oral drink solution (pH of 1.2 to 1.3).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8283672c-619f-fe60-3d25-040f95ac1440 (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Absorption Relative bioavailability of nilotinib capsule is approximately 50%, as compared to an oral drink solution (pH of 1.2 to 1.3).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c0bc799-ce6a-822a-e063-6394a90ab748 (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Absorption Relative bioavailability of nilotinib capsule is approximately 50%, as compared to an oral drink solution (pH of 1.2 to 1.3).

  10. Projected row 1090

    Medicine slug
    nilotinib
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    11
    Source count
    11
    Agreement rate
    0.636364
    Recorded readings

    1. 17 hours

      Numeric value
      17
      Unit
      hours
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13b46e09-62d2-4ce9-b3c0-deafcb1f1842 (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Elimination The mean (CV%) apparent elimination half-life is estimated to be approximately 17 hours (69%) and the mean (CV%) apparent clearance approximates 29 L/h (61%).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6093952a-5248-45cb-ad17-33716a411146 (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Elimination The mean (CV%) apparent elimination half-life is estimated to be approximately 17 hours (69%) and the mean (CV%) apparent clearance approximates 29 L/h (61%).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:805cc504-60bb-7743-5ada-679eb3badc7f (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Elimination The mean (CV%) apparent elimination half-life is estimated to be approximately 17 hours (69%) and the mean (CV%) apparent clearance approximates 29 L/h (61%).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86dc5507-ae0a-43d2-8d5e-5b0568ce9c5e (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Elimination The mean (CV%) apparent elimination half-life is estimated to be approximately 17 hours (69%) and the mean (CV%) apparent clearance approximates 29 L/h (61%).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b34e7fd4-53c5-46d8-bf8a-1fcbe7a16504 (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Elimination The mean (CV%) apparent elimination half-life is estimated to be approximately 17 hours (69%) and the mean (CV%) apparent clearance approximates 29 L/h (61%).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8283672c-619f-fe60-3d25-040f95ac1440 (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Elimination The mean (CV%) apparent elimination half-life is estimated to be approximately 17 hours (69%) and the mean (CV%) apparent clearance approximates 29 L/h (61%).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c0bc799-ce6a-822a-e063-6394a90ab748 (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Elimination The mean (CV%) apparent elimination half-life is estimated to be approximately 17 hours (69%) and the mean (CV%) apparent clearance approximates 29 L/h (61%).

    2. 10 hours

      Numeric value
      10
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c67b81f-9a44-446a-a24f-bbecbbf88979 (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Elimination The mean (CV%) elimination half-life of nilotinib is 10 hours (30%) following a single dose of Nilotinib Capsules 200 mg (0.5 times the maximum approved recommended dose) in fasted healthy subjects.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e27c3e09-bc4f-4f01-be05-1c43ac72285d (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Elimination The mean (CV%) elimination half-life of nilotinib is 10 hours (30%) following a single dose of Nilotinib Capsules 200 mg (0.5 times the maximum approved recommended dose) in fasted healthy subjects.

    3. 13.6 h

      Numeric value
      13.6
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:98b197ea-bca4-427e-8737-97f70a3262bc (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Elimination The geometric mean (coefficient of variation) apparent first-order terminal elimination half-life was 13.6 h (36.4%) for a single 160 mg dose of CAVHANZA.

    4. 14 hours

      Numeric value
      14
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d288d165-3505-49bb-9b2e-124490d65f49 (opens source in a new tab)

        Nilotinib label

        Version not recorded · Effective date not recorded

        Elimination The mean elimination half-life of nilotinib is approximately 14 hours.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=1080

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy